Monitor the upcoming FDA meeting in Q2 2026 for guidance on the belapectin development path; the S-3 shelf registration increases the likelihood of a capital raise, potentially dilutive to shareholders.
Price Chart
Executive Summary
Galectin Therapeutics reported a net loss of $31.0 million for 2025, with EPS of ($0.48), missing consensus of ($0.06) due to lower R&D expenses from the conclusion of its NAVIGATE trial. The company secured a $10 million line of credit, extending its cash runway to April 2027, and highlighted positive biomarker data from its belapectin program for MASH cirrhosis. This filing follows a recent S-3 shelf registration, suggesting capital flexibility.
Key Financial Metrics
Key Facts
- Net loss applicable to common stockholders was $31.0 million ($0.48 per share) for 2025, compared to $47.2 million ($0.76 per share) in 2024.
- R&D expenses decreased to $14.3 million from $36.6 million in 2024 due to the conclusion of the NAVIGATE clinical trial.
- Cash and cash equivalents were $17.7 million as of December 31, 2025, with an additional $10 million line of credit, funding operations through April 2027.
- Positive 18-month biomarker data from the NAVIGATE trial showed consistent antifibrotic activity for belapectin in MASH cirrhosis, including reduced portal hypertension risk.
- The company filed an S-3 shelf registration 21 days prior, enabling up to $200 million in future offerings.
Financial Impact
Reduced R&D spend lowered net loss by $16.2 million YoY, but EPS missed consensus by 33.3%. $27.7 million in total liquidity provides near-term funding.
Risk Factors
- Clinical trial results have not yet led to regulatory approval, and future studies may require significant funding.
- The S-3 shelf registration creates potential for shareholder dilution if the company issues new equity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-012158 |
| Document: ef20068722_8k.htm | 0001140361-26-012158 |
| Document: 0001140361-26-012158-index-headers.html | 0001140361-26-012158 |
| Document: 0001140361-26-012158-index.html | 0001140361-26-012158 |
| Document: 0001140361-26-012158.txt | 0001140361-26-012158 |
| 8-K Data (Synthetic) | 0001140361-26-012158 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.21 (−13.01%) |
Oct 13, 2026 14d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.21 (+13.01%) |
Oct 6, 2026 21d ago | Press Release | $3.76 | awaiting T+20 | — | $3.21 (−14.63%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.21 (−6.69%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.21 (−6.69%) |
Aug 4, 2026 12w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.21 (+7.36%) |
Jun 30, 2026 16w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.21 (−25.87%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.21 (+47.93%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.21 (+47.93%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.21 (+36.60%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers